Alzheimer's Disease Drugs

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (15 January 2010) | Viewed by 24486

Special Issue Editor


E-Mail
Guest Editor
Psychiatry and Medical Psychology Department, University Hospital of Besançon, Besançon, France

Special Issue Information

Dear Colleagues,

One of the main purpose of Alzheimer disease treatment is to improve cognitive abilities- such as memory and thinking and also slow progression of the disease. Despite many promising research current treatments cannot cure or halt the disease, but can offer some people modest improvement in some symptoms.

Alzheimer’s disease drugs are coming from 2 main categories: drugs to treat cognitive symptoms and drugs to treat specific behavioral disturbances that do not respond to non-pharmacological behavioral-management approaches. Prevention treatment are also of some importance.

Research into Alzheimer’s is focused on different possible treatments such as increasing the efficiency of the damaged nerve cells, preventing production and inhibiting the build-up of beta amyloid proteins, protecting nerve cells from the damaging effects of hydrogen peroxide.

If cholinestérase inhibitors are the first drugs developped, recent progress have highlited other drugs with different targets such as amyloid plaques or neurofibrillary tangles. Alzheimer’s vaccine, secretase modulators, anti-inflammatory drugs or even some antibiotics have been tested and seem to interfere with the development of amyloid plaques in the brain. Countless new treatments are in development, so more options will be available in the near future.

The purpose of this special issue is to assess the current status of AD drugs and perspective of new treatment stratégies through comprehensive reviews or original research datas.

Prof. Dr. Pierre Vandel
Guest Editor

Keywords

  • alzheimer disease
  • cognitive behavior disorder
  • memory
  • beta amyloid
  • antioxydants
  • cholinesterase inhibitors
  • vaccine
  • prevention

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

182 KiB  
Article
Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer's Disease and Related Disorders
by Renaud David, Emmanuel Mulin, Patrick Mallea and Philippe H. Robert
Pharmaceuticals 2010, 3(8), 2387-2397; https://doi.org/10.3390/ph3082387 - 26 Jul 2010
Cited by 9 | Viewed by 9546
Abstract
Behavioral and psychological symptoms (BPSD) are now known to be frequently associated to cognitive and functional decline in Alzheimer‘s disease and related disorders. They are present since the early stages of the disease and have negative impact on the disease process. BPSD assessment [...] Read more.
Behavioral and psychological symptoms (BPSD) are now known to be frequently associated to cognitive and functional decline in Alzheimer‘s disease and related disorders. They are present since the early stages of the disease and have negative impact on the disease process. BPSD assessment is crucial in clinical practice and also in future clinical trials targeting disease-modifying therapies for dementia. In this article, we will first review current assessment tools for BPSD, mainly global and domain-specific scales, and new assessment methods, currently available or in development, including new scales, diagnostic criteria and new technologies such as ambulatory actigraphy. Full article
(This article belongs to the Special Issue Alzheimer's Disease Drugs)

Review

Jump to: Research

524 KiB  
Review
Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants
by Ramón Cacabelos, Lucía Fernández-Novoa, Rocío Martínez-Bouza, Adam McKay, Juan C. Carril, Valter Lombardi, Lola Corzo, Iván Carrera, Iván Tellado, Laura Nebril, Margarita Alcaraz, Susana Rodríguez, Ángela Casas, Verónica Couceiro and Antón Álvarez
Pharmaceuticals 2010, 3(10), 3040-3100; https://doi.org/10.3390/ph3103040 - 29 Sep 2010
Cited by 35 | Viewed by 14309
Abstract
About 80% of functional genes in the human genome are expressed in the brain and over 1,200 different genes have been associated with the pathogenesis of CNS disorders and dementia. Pharmacogenetic studies of psychotropic drug response have focused on determining the relationship between [...] Read more.
About 80% of functional genes in the human genome are expressed in the brain and over 1,200 different genes have been associated with the pathogenesis of CNS disorders and dementia. Pharmacogenetic studies of psychotropic drug response have focused on determining the relationship between variations in specific candidate genes and the positive and adverse effects of drug treatment. Approximately, 18% of neuroleptics are substrates of CYP1A2 enzymes, 40% of CYP2D6, and 23% of CYP3A4; 24% of antidepressants are substrates of CYP1A2 enzymes, 5% of CYP2B6, 38% of CYP2C19, 85% of CYP2D6, and 38% of CYP3A4; 7% of benzodiazepines are substrates of CYP2C19 enzymes, 20% of CYP2D6, and 95% of CYP3A4. 10-20% of Western populations are defective in genes of the CYP superfamily; and the pharmacogenomic response of psychotropic drugs also depends on genetic variants associated with dementia. Prospective studies with anti-dementia drugs or with multifactorial strategies have revealed that the therapeutic response to conventional drugs in Alzheimer’s disease is genotype-specific. The disease-modifying effects (cognitive performance, biomarker modification) of therapeutic intervention are APOE-dependent, with APOE-4 carriers acting as the worst responders (APOE-3/3 > APOE-3/4 > APOE-4/4). APOE-CYP2D6 interactions also influence the therapeutic outcome in patients with dementia. Full article
(This article belongs to the Special Issue Alzheimer's Disease Drugs)
Show Figures

Figure 1

Back to TopTop